These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23601457)

  • 21. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
    Sullivan BD; Crews LA; Sönmez B; de la Paz MF; Comert E; Charoenrook V; de Araujo AL; Pepose JS; Berg MS; Kosheleff VP; Lemp MA
    Cornea; 2012 Sep; 31(9):1000-8. PubMed ID: 22475641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research update of effectiveness and mechanism of essential fatty acids in treating dry eye].
    Liu Y; Liang QF
    Zhonghua Yan Ke Za Zhi; 2017 Mar; 53(3):225-229. PubMed ID: 28316198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathophysiology, diagnosis, and treatment of dry eye disease.
    Messmer EM
    Dtsch Arztebl Int; 2015 Jan; 112(5):71-81; quiz 82. PubMed ID: 25686388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study.
    Chan CK; Lam DS
    Am J Ophthalmol; 2004 Jun; 137(6):1157-8; author reply 1158. PubMed ID: 15183818
    [No Abstract]   [Full Text] [Related]  

  • 26. Dexamethasone nanowafer as an effective therapy for dry eye disease.
    Coursey TG; Henriksson JT; Marcano DC; Shin CS; Isenhart LC; Ahmed F; De Paiva CS; Pflugfelder SC; Acharya G
    J Control Release; 2015 Sep; 213():168-174. PubMed ID: 26184051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mass and solute balance model for tear volume and osmolarity in the normal and the dry eye.
    Gaffney EA; Tiffany JM; Yokoi N; Bron AJ
    Prog Retin Eye Res; 2010 Jan; 29(1):59-78. PubMed ID: 19944776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on dry eye disease molecular treatment: advances in drug pipelines.
    Colligris B; Crooke A; Huete-Toral F; Pintor J
    Expert Opin Pharmacother; 2014 Jul; 15(10):1371-90. PubMed ID: 24773445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for anti-inflammatory therapy in dry eye syndrome.
    de Paiva CS; Pflugfelder SC
    Arq Bras Oftalmol; 2008; 71(6 Suppl):89-95. PubMed ID: 19274418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tear hyperosmolarity on conjunctival cells in mild to moderate dry eye.
    Julio G; Lluch S; Pujol P; Merindano MD
    Ophthalmic Physiol Opt; 2012 Jul; 32(4):317-23. PubMed ID: 22620852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD.
    Ogawa Y; Dogru M; Uchino M; Tatematsu Y; Kamoi M; Yamamoto Y; Ogawa J; Ishida R; Kaido M; Hara S; Matsumoto Y; Kawakita T; Okamoto S; Tsubota K
    Bone Marrow Transplant; 2010 Mar; 45(3):565-9. PubMed ID: 19633693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of dry eye disease.
    Lemp MA
    Am J Manag Care; 2008 Apr; 14(3 Suppl):S88-101. PubMed ID: 18452372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lodoxamide as adjuvant therapy in patients with dry eye.
    Petricek I; Pokupec R; Petricek G; Salopek-Rabatić J
    Coll Antropol; 2001; 25 Suppl():149-52. PubMed ID: 11817007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative costs of various preserved artificial tear solutions for the treatment of dry eye conditions.
    Enzenauer RW; Kao A; Williams T; Lambert RW
    Eye Contact Lens; 2003 Oct; 29(4):238-40. PubMed ID: 14555900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of ocular inflammatory conditions with loteprednol etabonate.
    Pavesio CE; Decory HH
    Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing trends in the treatment of dry-eye disease.
    Dogru M; Nakamura M; Shimazaki J; Tsubota K
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1581-601. PubMed ID: 24088227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.
    Solomon A; Dursun D; Liu Z; Xie Y; Macri A; Pflugfelder SC
    Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2283-92. PubMed ID: 11527941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rose bengal staining as an assessment of ocular surface damage and recovery in dry eye disease-a review.
    Doughty MJ
    Cont Lens Anterior Eye; 2013 Dec; 36(6):272-80. PubMed ID: 23928365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Inflammatories in the Treatment of Dry Eye Disease: A Review.
    Perez VL; Mah FS; Willcox M; Pflugfelder S
    J Ocul Pharmacol Ther; 2023 Mar; 39(2):89-101. PubMed ID: 36796014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.